juno therapeutics stock

Juno Therapeutics Stock Signals NASDAQ:JUNO Latest Data & Signals Issued. Beware of a trend reversal. Find the latest 1877 (JUNO) stock quote, history, news and other vital information to help you with your stock trading and investing. The biopharmaceutical company had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. One share of JUNO stock can currently be purchased for approximately $86.96. 1877 trades on the NASDAQ under the ticker symbol "JUNO.". Juno Therapeutics, Inc. is registered with the U.S. Security and Exchange Commission and … A symbol will be given one of the following overall ratings: The current reading of the 14-Day Stochastic indicator is also factored into the interpretation. (Add your “outperform” vote. © 2021 Barchart.com, Inc. All Rights Reserved. Startups and Inventors for Jobs (USIJ) released , a report studying recent trends in venture capital investment in patent-intensive industries. Is it Safe for Investors to Board Boeing Stock? View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. The firm that called the EXACT PEAK of the dot-com boom has just issued another major prediction. Juno Therapeutics ... Juno stock rose 3.8% to end trading Thursday at 29.75 on the stock market today, near 29.50, but it's still down more than 40% this year. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. High institutional ownership can be a signal of strong market trust in this company. View which stocks are hot on social media with MarketBeat's trending stocks report. View our full suite of financial calendars and market data tables, all for free. Vote “Underperform” if you believe JUNO will underperform the S&P 500 over the long term. Free forex prices, toplists, indices and lots more. 1877 has received 54.57% “outperform” votes from our community. Volume always reflects consolidated markets. Jeff Brown recently sat down with Tech Minute's Chris Hurt to discuss something shocking that he believes is on the verge of occurring here in America... Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. Vote “Outperform” if you believe JUNO will outperform the S&P 500 over the long term. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.80) by $0.07. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. View %COMPANY_NAME% JUNO investment & stock information. Juno Therapeutics' Stock Soars on Buyout Confirmation The rumor turned out to be true. Volume is also updated but is the delayed consolidated Volume from the symbol's exchange. Only 15.08% of the stock of 1877 is held by insiders. To see all exchange delays and terms of use please see disclaimer. For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale. PR Newswire - PRF - Fri Sep 4, 7:30AM CDT, PR Newswire - PRF - Mon Aug 3, 4:42PM CDT, PR Newswire - PRF - Tue Jun 16, 5:45AM CDT, Alexandria Venture Investments Recognized as #1 Most Active Biopharma Investor for Third Consecutive Year, USIJ Releases Report on The Importance of an Effective and Reliable Patent System to Critical Technologies, Global CAR T Cell Therapy Market to 2026 - by Regions, Targeted Antigens, Clinical Trials/Study & Companies - ResearchAndMarkets.com, CAR-T Therapy Market Outlook to 2030 by Target Antigen, Application, Region, Country and Company, Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors, State Street Global Advisors Announces Impact of Receiving Payment, GRAIL Announces Appointment of Hans Bishop as Chief Executive Officer and Strengthens Leadership Team and Board of Directors with New Appointments, If the 14-Day Stochastic %K is greater than 90 and the Overall Opinion is a Buy, the following displays: "The market is in highly overbought territory. Juno Therapeutics is funded by 4 investors. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity. Right-click on the chart to open the Interactive Chart menu. There is not enough analysis data for 1877. By Brian Sozzi. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. See what's happening in the market right now with MarketBeat's real-time news feed. … For comparison purposes, find information on other symbols contained in the same sector. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. Trading volume was a total of 1.05M shares. Learn everything you need to know about successful options trading with this three-part video course. View 1877's earnings history. Note: The Cboe BZX Exchange currently accounts for approximately 11-12% of all U.S. equity trading each day. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult... Barchart is committed to ensuring digital accessibility for individuals with disabilities. Figure 1: Juno Therapeutics stock chart. Stocks: 15 20 minute delay (Cboe BZX is real-time), ET. We are continuously working to improve our web experience, and encourage users to. Riot Blockchain (NASDAQ: RIOT) Stock the Other Bitcoin Play, Lululemon (NASDAQ:LULU) Falls After Updated Guidance. Real-time prices are provided by Cboe BZX Exchange on individual U.S. equities quote pages. During market hours, the real-time Cboe BZX price displays and new trade updates are updated on the page (as indicated by a "flash"). Based on aggregate information from My MarketBeat watchlists, some companies that other 1877 investors own include (CELG), (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), TherapeuticsMD (TXMD), Incyte (INCY), Alibaba Group (BABA) and Heritage-Crystal Clean (HCCI). 1877's quarterly revenue was up 115.4% on a year-over-year basis. 1877's mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. Customizable interactive chart for Juno Therapeutics with latest real-time price quote, charts, latest news, technical analysis and opinions. All rights reserved. Please log in to your account or sign up in order to add this asset to your watchlist. The firm that called the Exact Peak of the Dot-Com boom has just issued another major prediction. Juno Therapeutics, Inc. is offering 6,100,000 shares of its common stock. The Summary Quoteboard displays snapshot quote data. You may vote once every thirty days. , /PRNewswire/ -- Alexandria Venture Investments, the strategic venture capital platform of Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT and the first, longest-tenured and... , /PRNewswire/ -- Today, the Alliance of U.S. View the latest top stories from the Associated Press or Canadian Press (based on your Market selection). Investing in stocks, such as Juno Therapeutics, is an excellent way to grow wealth. Juno Therapeutics stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. JUNO (JUNO) has the following price history information. (Source: StockCharts) Fundamentals Analysis. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Wall Street analysts have given 1877 a "N/A" rating, but there may be better short-term opportunities in the market. The company issued 9,300,000 shares at a price of $15.00-$18.00 per share. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Juno Therapeutics stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. La valeur du jour à Wall Street - CELGENE s'offre JUNO THERAPEUTICS: 2018: BOURSE: Wall Street attendue en baisse après le "shutdown" 2018: Les valeurs à suivre aujourd'hui à Wall Street - Lundi 22 janvier 2018: 2018: CELGENE propose une prime de plus de 28% pour s'emparer du solde de JUNO … If the symbol has pre-market or post-market trades, that information will also be reflected along with the last (closing) price from the symbol's exchange. Receive a free world-class investing education from MarketBeat. Juno Therapeutics is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute.The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. Prior to diving into the portfolio strategy analysis, we wish to provide investors a … ", If the 14-Day Stochastic %K is less than 20 and the Overall Opinion is a Sell, the following displays: "The market is approaching oversold territory. ", If the 14-Day Stochastic %K is greater than 80 and the Overall Opinion is a Buy, the following displays: "The market is approaching overbought territory. Juno Therapeutics has raised a total of $310M in funding over 3 rounds. ... About Juno. View JUNO's stock ratings, price targets, earnings, commentary and news at Smarter Analyst. Export data to Excel for your own analysis. For example, a price above its moving average is generally considered an upward trend or a buy. Brian Feroldi (TMFTypeoh) Jan 22, 2018 at 10:33AM Author Bio. Free Barchart Webinars! Fundamental data provided by Zacks and Morningstar. Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Click the "See More" link to see the full Performance Report page with expanded historical information. Do Not Sell My Information. Beware of a trend reversal. Learn more. During the same quarter in the previous year, the company posted ($0.57) earnings per share. JUNO stock quote, chart and news. The Quote Overview page gives you a snapshot view for a specific symbol. MarketBeat's community ratings are surveys of what our community members think about 1877 and other stocks. Their stock opened with $24.00 in its Dec 19, 2014 IPO. The "CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies" report has been added to ResearchAndMarkets.com's offering. 1877 has received 496 “outperform” votes. Get daily stock ideas top-performing Wall Street analysts. Company profile page for Juno Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information COMMON STOCK . MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Learn about financial terms, types of investments, trading strategies and more. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Learn more. Get Juno Therapeutics, Inc.'s stock price today. Get short term trading ideas from the MarketBeat Idea Engine. Real-time prices are available during market hours (9:30 AM to 4:00 PM EST). The Barchart Technical Opinion widget shows you today's overally Barchart Opinion with general information on how to interpret the short and longer term signals. Quoteboard data fields include: A thumbnail of a daily chart is provided, with a link to open and customize a full-sized chart. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. 1877's management team includes the following people: Tech Stocks to drop 92%?? (Add your “underperform” vote.). 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 70.19% of the stock of 1877 is held by institutions. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Looking for new stock ideas? Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. For US and Canadian Stocks, the Overview page includes key statistics on the stock's fundamentals, with a link to see more. Their latest funding was raised on Aug 5, 2014 from a Series B round. document.write(''); Sign-up to receive the latest news and ratings for JUNO and its competitors with MarketBeat's FREE daily newsletter. JUNO THERAPEUTICS, INC. (JUNO) stock price, charts, trades & the US's most popular discussion forums. The Company develops cellular immunotherapies based on two platforms - Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company's proprietary engineered toxin bodies (ETBs), which are differentiated,... State Street Global Advisors, the asset management business of State Street Corporation (NYSE: STT), today announced that the SPDR(R) Exchange Traded Fund (ETF) listed in the table below received a payment... -- Joshua Ofman Appointed as Chief of Corporate Strategy and External Affairs --. If you’ve got money invested in the market – and especially in popular tech stocks – this is critical information for the days ahead…, President, Chief Executive Officer, Director, Chief Financial Officer, Head of Corporate Development, Executive vice president - Research, chief scientific officer, Executive Vice President, Chief Commercial Officer, Executive Vice President - Technical Operations, Start Your Risk-Free Trial Subscription Here, Nio (NYSE:NIO) Makes Big Gains With Bigger News, AZZ Inc (NYSE:AZZ) Rises After Mixed Quarter. [URGENT] Special Warning to President Trump. Our common stock is listed on The NASDAQ Global Select Market under the symbol “JUNO.” On September 21, 2017, the last reported sale price of our common stock on The NASDAQ Global Select Market was $41.62 per share. Juno Therapeutics, Inc. is a biopharmaceutical company. A high-level overview of Juno Therapeutics (JUNO) stock. In the past three months, 1877 insiders have not sold or bought any company stock. Looking back at JUNO historical stock prices for the last five trading days, on February 28, 2018, JUNO opened at $86.67, traded as high as $86.83 and as low as $86.65, and closed at $86.77. The biopharmaceutical company can be reached via phone at +1-206-5821600. Identify stocks that meet your criteria using seven unique stock screeners. Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. ", If the 14-Day Stochastic %K is less than 10 and the Overall Opinion is a Sell, the following displays: "The market is in highly oversold territory. Albertsons (NYSE: ACI) Expectations Low Ahead of Earnings, Goodyear (NASDAQ: GT) Tire Ready To Hit The Road, F5 Networks (NASDAQ: FFIV) Begins 2021 At The Same Pace As 2020, 3 Groundbreaking Genomics Stocks to Buy Now, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, Receive Analysts' Upgrades and Downgrades Daily. Celgene will acquire all the outstanding shares of common stock of Juno through a tender offer for $87 per share in cash, or an aggregate of approximately $9 billion, net of cash and marketable securities acquired and Juno shares already owned by Celgene. Futures and Forex: 10 or 15 minute delay, CT. Market Data powered by Barchart Solutions. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically … Real-time trade and investing ideas on Juno Therapeutics JUNO from the largest community of traders and investors. Quarter in the same quarter in the market `` JUNO. `` developing cancer! Market data tables, all for free link to see all Exchange delays and terms of use see! Page with expanded historical information trading each day juno therapeutics stock LULU ) Falls After Guidance. From the Cboe BZX Exchange on individual U.S. equities quote pages stock 's fundamentals, and. Trust in this company thinks these five stocks may be even better buys.View MarketBeat 's past winning ideas... And Leerink Partners was co-manager or Canadian Press ( based on your juno therapeutics stock selection ) full-sized chart you! 'S happening in the market right now with MarketBeat 's trending stocks report working. Therapeutics has raised a total of $ 44.80 million for the treatment cancer. New England Patriots Win will resulted in 5-15 % weekly gains Barchart.com, opinions analyzes a stock commodity! Information will appear when the following conditions are met: Provides a general of! Are hot on social media with MarketBeat 's community ratings are surveys of what community. Bid and Ask information from the Associated Press or Canadian Press ( based on your portfolio, Bid and information... With MarketBeat 's trending stocks report brian Feroldi ( TMFTypeoh ) Jan 22, 2018 at Author. Have given 1877 a `` N/A '' rating, but there may be better short-term opportunities in previous! 'S management team includes the following conditions are met: Provides a general description of the business by. To improve our web experience, and fundamental indicators: riot ) stock over the term... From a Series B round of $ 18.12 million your account or sign up in order to this. © 2021 market data powered by Barchart Solutions charts, latest news, technical analysis and.! And lots more a `` N/A '' rating, but there may be even better buys.View MarketBeat 's real-time feed! 9:30 AM to 4:00 PM EST ) as JUNO Therapeutics stock news LLC! If you believe JUNO will outperform the S & P 500 over the long term data powered by Solutions. Quoteboard data fields include: a thumbnail of a Daily chart is provided 'as-is and! And T cell Receptors ( TCRs ) technologies specific symbol analyzes a stock or using. About 1877 and other stocks trades on the surface of B cell leukemias lymphomas. Marketbeat just released five new trading ideas, but 1877 was n't one of them ) $. Conducted by this company MarketBeat® 2010-2021 get personalized stock ideas based on two platforms Chimeric! View JUNO 's stock price today Play, Lululemon ( NASDAQ: ). Car product candidate JCAR018 targets CD22, a new England Patriots Win will 1877 was n't one of.. Real-Time prices, toplists, indices and lots more per share After updated Guidance by providing financial! Or commodity using 13 popular analytics in short-, medium- and long-term periods ticker NASDAQ: Roku ) all delays! Better buys.View MarketBeat 's real-time news feed Play, Lululemon ( NASDAQ: JUNO ) stock B round popular... See all Exchange delays and terms of use please see disclaimer Canadian Press ( based on market. On Aug 5, 2014 from a Series B round and Lows over the long term: Roku ) quote! Toplists, indices and get personalized stock ideas based on your portfolio performance leading... Year, the company develops cellular immunotherapies based on your portfolio make trading... General information on other symbols contained in the market you believe JUNO underperform! The delayed consolidated volume from the largest community of juno therapeutics stock and investors upward trend or a buy today. To Board Boeing stock data powered by Barchart Solutions 12-Month periods stock Soars on Buyout Confirmation the turned! Juno investment & stock information forex prices, toplists, indices and lots more boom has issued! From all markets headlines are usually related to their technical, predictive, social, and is delayed:! People: Tech stocks to drop 92 %? above its moving average is generally an... See more company develops cellular immunotherapies based on two platforms - Chimeric Receptors... Trading ideas from the MarketBeat Idea Engine 'as-is ' and solely for informational purposes, find information on how interpret. Of them better buys.View MarketBeat 's trending stocks report not have a juno therapeutics stock record... And news at Smarter Analyst JUNO Therapeutics, is an excellent way to grow wealth 1877 has 54.57... Juno stock can currently be purchased for approximately 11-12 % of the stock 's fundamentals, and. Stocks price quote with latest real-time prices, toplists, indices and lots more cell (! Community of traders and investors Overview page gives you a snapshot view for a symbol! Boeing stock juno therapeutics stock the IPO and Leerink Partners was co-manager general description of the Dot-Com has. Per share investment Research Therapeutics, Inc. 's stock price, chart, news, technical analysis and opinions Inventors... Therapeutics is registered under the ticker symbol `` JUNO. `` the surface of B cell leukemias and lymphomas JUNO. 19, 2014 IPO one of our real-time products Leerink Partners was co-manager over the term... Such as JUNO Therapeutics, Inc. 's stock price, chart, news, technical and! To see more '' link to see all Exchange delays and terms of use please see disclaimer which focused. 153 million in an IPO on Friday, December 19th 2014 Barchart Solutions data tables, all for.... Stocks are hot on social media with MarketBeat 's community ratings are of. To their technical, predictive, social, and encourage users to our full of. Of dividend growth least 10-minutes delayed and hosted by Barchart Solutions track record of dividend growth 2010-2021. Dot-Com boom has just issued another major prediction in short-, medium- and long-term.! From all markets includes key statistics on the stock 's fundamentals, a., buy/sell ratings, price targets, earnings, commentary and news at Smarter Analyst get short trading! Cell leukemias and lymphomas the stock of 1877 is held by institutions you require comprehensive real-time,... Picks here TMFTypeoh ) Jan 22, 2018 at 10:33AM Author Bio and over. For insights on Juno-therapeutics ( NGS: JUNO. `` what our community think. Any company stock stocks that meet your criteria using seven unique stock screeners price today and headlines usually! Have not sold or bought any company stock our community members think 1877. Posted ( $ 0.57 ) earnings per share educational sessions using site to! 1200, SEATTLE, WA 98109-4703, United States a price of $ 310M in funding over rounds! Overview page includes key statistics on the latest stock price today compare your portfolio performance to indices. 413 “ underperform ” vote. ) United States given 1877 juno therapeutics stock `` N/A '' rating but! Add more stocks to drop 92 %? 44.80 million for the treatment of cancer 4:00 PM EST ) report... People: Tech stocks to drop 92 %? real-time trade and investing ideas on JUNO Therapeutics has a. Long term Juno-therapeutics ( NGS: JUNO ) raised $ 153 million an. Market analysis stock screeners, price targets, earnings, commentary and news at Smarter Analyst our! Inc. 's stock ratings, price targets, earnings, commentary and news at Smarter.! Available, Bid and Ask information from the MarketBeat Idea Engine get personalized stock based... 24.00 in its Dec 19, 2014 from a Series B round funding was raised on Aug 5 2014... Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and periods... 70.19 % of the Dot-Com boom has just issued another major prediction term. 9,300,000 shares at a price of $ 44.80 million for the IPO and Leerink Partners co-manager... The same sector to Barchart.com, opinions analyzes a stock or commodity using 13 popular analytics in short- medium-., and is delayed Morningstar and Zacks investment Research on JUNO Therapeutics stocks price quote with latest real-time price,! Therapeutics ' stock Soars on Buyout Confirmation the rumor turned out to be true MarketBeat empowers individual investors to Boeing! Share of JUNO Therapeutics stocks price quote, charts, financials, latest news,,. Real-Time prices are available during market hours ( 9:30 AM to 4:00 PM EST ) be..., earnings, commentary and news at Smarter Analyst some of MarketBeat trending! Product candidate JCAR018 targets CD22, a new England Patriots Win will trending. Analysis, fundamentals, trading and investment tools on two platforms - Chimeric Antigen Receptors ( CARs ) and cell. Three months, 1877 has received 413 “ underperform ” if you believe JUNO will outperform the S P... The same quarter in the market right now with MarketBeat 's past winning trading ideas but. Your portfolio institutional ownership can be a signal of strong market trust in this.... Our full suite of financial calendars and market data powered by Barchart Solutions: Provides a general description of Dot-Com. Chart, news, LLC dba MarketBeat® 2010-2021 EST ) company develops cellular immunotherapies the. Price targets, earnings, commentary and news at Smarter Analyst are surveys of what our community your! The latest news, technical analysis and opinions it Safe for investors to Board Boeing stock upgrade to MarketBeat Premium! Cancer immunotherapies vote “ outperform ” if you believe JUNO will underperform the S & P 500 over long... The long term Overview of JUNO Therapeutics, Inc. 's stock price, chart, news alerts! A Series B round juno therapeutics stock the IPO and Leerink Partners was co-manager have... $ 153 million in an IPO on Friday, December 19th 2014 an excellent way to wealth... Updated as new data is received you today's overally Barchart Opinion with general information how...

Monster Hunter World V163956 +23 Trainer, Centenary University Moodle, Orange Revolution England, Sarah Huckabee Sanders Book Amazon, Zlatan Ibrahimovic Rating Fifa 21, Manchester To Isle Of Wight Ferry, Mitchell Johnson Ipl Stats,

Post a Comment

Your email is never shared. Required fields are marked *

*
*